Forxiga is the only inhibitor of sodium-glucose-cotransporter type 2 (SGLT-2) with proven efficacy and safety for 4 years of use. One tablet a day, regardless of food intake, ensures a stable decrease in blood pressure, a significant and persistent decrease in glycated hemoglobin, a steady decrease in body weight. The drug is not indicated for the treatment of obesity and hypertension. The results were secondary endpoints in clinical trials.
Dapagliflozin (an active ingredient of Forxiga) was registered in monotherapy for the treatment of type 2 diabetes, and also in combination with Metformin as a starting drug and with a progressive course of the disease.
Today, the accumulated experience makes it possible to use the medication for diabetics in all possible combinations:
- with sulfonylurea derivatives (including complex therapy with metformin);
- with gliptins;
- with thiazolidinediones;
- with DPP-4 inhibitors (possibly combined with metformin and analogs);
- with insulin (plus oral hypoglycemic agents).
Recommendations for use
The oral tablets are used at any time of day, regardless of food. Tablets with 5 mg and 10 mg dosages are packed in the amount of 28, 30, 56 and 90 pieces. The standard recommended dosage is 10 mg/day. One or two tablets, depending on the dosage, should be taken once along with water.
If liver function is impaired, the doctor reduces the norm by one and a half to two times (with initial therapy 5 mg/day).
To prevent hypoglycemia, you should carefully us Forxiga with an insulin therapy and in combination with medications of the sulfonylurea group.
For maximum effectiveness, it is advisable to take the medicine at the same time of day.
Advantages of Forxiga
- Efficiency does not depend on the sensitivity of tissues to insulin;
- The mechanism of action does not load β-cells;
- Mediated enhancement of β-cell potency;
- Decreased insulin resistance;
- Minimal risk of hypoglycemia, compared to placebo.
- The hypoglycemic effect of the medication is guaranteed for any condition of the pancreas and β-cells.
But in spite of the fact that the mechanism of action of the drug is insulin-dependent, one can expect an indirect improvement in the functions of β-cells and due to the primary mechanisms of action of improving the sensitivity of tissues to insulin.
The duration of the disease does not affect the ability of dapagliflozin. Unlike other analogs, effective only the first 10 years of development of diabetes, Forxiga can be successfully used in case of “experienced” diabetes.
After the end of the course of taking the inhibitor, the therapeutic effect persists long enough. It depends on the efficiency of the kidneys.
The drug helps hypertensives monitor blood pressure, providing an easy hypotensive effect. This, in turn, helps reduce the risk of developing cardiovascular conditions.
Forxiga quickly normalizes the indicators of muscle glycemia, but the concentration of cholesterol (both total and LDL) may increase.